How to Verify an Immunotherapy Vial Is Genuine
Immunotherapy vials are among the most expensive single items in Indian cancer care, and that has drawn counterfeiters and diverted stock into the supply chain around them. This page is a plain verification checklist: what to read on the pack, which batch and import details must agree, what India's QR-code rule does and does not yet require, and exactly what to do when something looks wrong. It is written to be printed and used at a pharmacy counter. It is a reference for checking a medicine, not a route to sourcing one.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
What should you check on an immunotherapy vial and its pack?
You cannot confirm a vial by looking at it. What you can verify is the chain it arrived through. Read the carton and the vial label together. Match the batch number and expiry across vial, carton and invoice. Confirm the vial was procured by the treating hospital's own pharmacy, from the manufacturer or an authorised distributor.
| What to check | What it should show | What should stop you |
|---|---|---|
| Outer carton seal | Intact, machine-sealed, never previously opened | A carton that has been slit, re-taped or re-glued |
| Brand name and generic name | Both printed — the generic name (pembrolizumab, nivolumab, atezolizumab and so on) clearly stated | A brand name with no generic name, or a generic name that differs from the prescription |
| Batch number ("B. No." or "Batch No.") | The same batch number on the vial label, the carton and the purchase invoice | A batch number that is missing, smudged, over-printed, or lifted off with solvent |
| Manufacturing and expiry dates | Both printed, and identical on vial and carton | An expired vial, or dates that disagree between vial and carton |
| Manufacturing licence number | Printed as "Mfg. Lic. No." on an India-made product | No licence number on a pack described as made in India |
| Import licence details (imported vials) | The words "Import Licence" with the licence number, plus the name and address of the Indian importer | An imported vial carrying no importer name, address or import licence number |
| Prescription-only marking | The Schedule H / "Rx" prescription warning printed on the label | A pack presented as something obtainable without a prescription |
| Bar code or QR code | Where present, it scans and returns details that match the printed pack | A code that will not scan, or returns details that contradict the label |
| Cold chain | Held at 2°C to 8°C throughout, in the hospital pharmacy's own refrigerator, never frozen | A vial carried home in a bag, left at room temperature, or frozen at any point |
| The solution itself | Clear or as described in that product's pack insert | Visible particles, unexpected colour, or a cracked or leaking vial |
Indicative guidance, as of August 2026, drawn from the labelling requirements of the Drugs Rules, 1945 and CDSCO's published guidance on identifying spurious drugs. It is a checklist for a conversation with the treating team and the hospital pharmacy — not a substitute for pharmacy-level verification.
Did you know?
In August 2026 the Delhi Police Crime Branch arrested 17 people, hospital staff among them, over an interstate trade in counterfeit and illegally diverted anti-cancer medicines. Investigators reported recovering 588 filled vials and around ₹9 crore of stock across Delhi-NCR, Mumbai and Hyderabad, and said original cartons were being re-used after batch numbers and MRP details had been removed with acetone. That single detail is the reason the batch number on a carton is something to check, not something to assume.
Does an immunotherapy vial in India have to carry a QR code?
Not yet, for most of them. The bar code and QR code requirement under Schedule H2 of the Drugs Rules, 1945 has applied to the top 300 drug brands since 1 August 2023. The Health Ministry notified an amendment on 25 June 2026 extending Schedule H2 to all anti-cancer medicines. That provision comes into force on 1 July 2027.
This matters because a lot of advice online is running ahead of the law. In August 2026 the absence of a QR code on an anti-cancer vial is not, by itself, evidence of a counterfeit. Many products simply are not covered yet. Manufacturers have been encouraged to adopt the codes voluntarily before the deadline, and some already have. Where a code is present and scans to details that match the printed pack, that is a genuine reassurance. Where it scans to something that contradicts the label, stop.
When the rule does apply, the code must sit on the primary packaging label — or the secondary label where the primary pack is too small — and must carry nine specified data elements:
- Unique product identification code
- Proper and generic name of the drug
- Brand name
- Name and address of the manufacturer
- Batch number
- Date of manufacture
- Date of expiry
- Manufacturing licence number
- Details of excipients
Source: Ministry of Health and Family Welfare notification of 25 June 2026 amending the Drugs Rules, 1945, and the earlier amendment G.S.R. 823(E) of 17 November 2022 which brought the top 300 brands under Schedule H2 with effect from 1 August 2023. Vaccines, narcotic and psychotropic drugs and anti-cancer medicines come under the expanded rule from 1 July 2027; antimicrobials from 1 July 2028.
What batch and import documentation should exist?
Three records, and they have to agree. A printed purchase invoice from the hospital pharmacy. The distributor's or importer's own supply record sitting behind it. And, on an imported pack, the import licence details printed on the label itself. If those three cannot be lined up, the vial cannot be traced.
- The purchase invoice. It should name the product, strength, batch number, expiry date, quantity, supplier and the supplier's drug licence number. Keep it — it is the paper trail if a batch is ever recalled.
- The batch number is the anchor. Everything else hangs off it. Three places, one number: vial label, carton, invoice.
- Imported packs carry more on the label, not less. Rule 96 of the Drugs Rules, 1945 requires the import licence number, preceded by the words "Import Licence", plus the name and address of the importer.
- Ask where the vial was bought from. A pharmacy procuring from the manufacturer or an authorised distributor answers that in one sentence, and no well-run oncology pharmacy takes offence at the question.
- No documentation, no infusion. A vial that arrives without an invoice cannot be verified afterwards, however convincing the pack looks.
- Government-scheme supply is not exempt. Medicine issued under a scheme should still be recorded against the named patient, with batch details in the file.
Who immunotherapy is not for, and what this page cannot do
Most people with cancer in India are not candidates for a checkpoint inhibitor at all. These medicines are approved for a defined set of cancers, and within those, eligibility usually turns on the stage of disease, on what treatment came before, and in several cancers on a biomarker result. A verification checklist does not widen who the medicine suits. It only helps confirm that a vial someone is already prescribed is what it claims to be.
Checkpoint inhibitors are also not suitable, without individual specialist assessment, for people with active or uncontrolled autoimmune disease, people taking high-dose immunosuppressive medicines, or organ transplant recipients. They work by lifting a brake on the immune system, which is exactly why those situations need an oncologist's judgment rather than a general rule from a web page.
And this page itself has limits worth stating plainly. It is not a way to source vials, and nothing here should be read as encouragement to buy immunotherapy outside a hospital. It is not a price list, and it attaches no CION rate to any named medicine. It makes no comparative quality claim between manufacturers or between brands. It does not say that CION stocks, supplies or dispenses any product named on this site. And it cannot replace laboratory testing — only a drug regulator can establish that a specific vial is spurious.
What should you do if you are not sure a vial is genuine?
Say so before it is infused, not after. Once a vial is opened and given, nothing about it can be verified. Raising a doubt delays one infusion by a few hours. Not raising it can mean a cycle of treatment that did nothing at all.
- Step 1 — Pause the infusion before the line is connected. A nurse or pharmacist can hold a dose while a batch is checked. This is a routine request.
- Step 2 — Keep the vial, the carton and the invoice together. Do not discard the outer box. It carries most of the evidence.
- Step 3 — Photograph the batch number, the expiry date and the full carton, front and back, before anything is handed back.
- Step 4 — Ask the hospital pharmacy to trace the batch to its purchase invoice and named distributor. A licensed pharmacy can do this from its own records.
- Step 5 — Ask the marketing company's Indian office to confirm the batch. Manufacturers maintain product-security teams and can say whether a batch number is one of theirs.
- Step 6 — Report it to a drug regulator. CDSCO's national helpline for drug-quality and spurious-drug complaints is 1800 11 1454. In Telangana, the Drugs Control Administration's toll-free number is 1800 599 6969. Both accept complaints from patients and families.
- Step 7 — Check the CDSCO monthly Drug Alert list on cdsco.gov.in, which publishes batches found to be not of standard quality or spurious.
- Step 8 — Tell the treating oncologist either way. A doubtful dose changes the treatment record, and the team needs to know before response is assessed.
Helpline numbers are published by CDSCO and the Telangana Drugs Control Administration and are given here as public safety information, current as of August 2026.
Where do fake and diverted vials actually come from?
Rarely from a factory pretending to be a factory. Published cases point at the edges of the legitimate chain: stolen packaging, diverted hospital stock, relabelled cartons and informal resale. Understanding the routes is what makes the checklist above useful rather than theatrical.
| Route | How it has been reported to work | What closes it off |
|---|---|---|
| Refilled genuine packaging | Authentic vials and cartons obtained from hospitals or pharmacies, then refilled and resealed. Europol has described this route; in a New Delhi case reported by ICIJ in April 2026, vials labelled as oncology medicines had been filled with an antifungal drug. | Intact seals, batch-carton-invoice matching, and hospital control over empty-vial disposal |
| Diverted hospital or scheme stock | Medicine bought or supplied for one patient, then resold elsewhere. The August 2026 Delhi case described stock diverted both from hospitals and from government supply. | Named-patient billing, batch details recorded in the file, and refusing vials offered privately by any individual |
| Relabelled packs | Batch numbers and MRP removed with solvent so the origin cannot be traced. Investigators in the August 2026 case reported acetone being used for exactly this. | Refusing any pack with a lifted, smudged or over-printed batch number |
| Online and messaging-app sellers | WHO and ICIJ reporting both describe falsified oncology medicines offered through social media, messaging apps and online marketplaces at prices below the legitimate market. | Never sourcing a prescription biologic online or through a chat app |
| Informal cross-border imports | A vial couriered from abroad by a relative or an agent, outside any import licence and outside any cold chain. | Routing a genuinely needed import through the hospital and the CDSCO permission route |
Drawn from routes described publicly by regulators, police and investigative reporting between 2024 and August 2026. This is general patient-safety information. It is not an allegation against any named hospital, pharmacy, distributor or manufacturer.
Is a cheaper immunotherapy vial always a counterfeit?
No — and families being priced out deserve a straight answer on this. Some immunotherapy prices in India have fallen legitimately. A nivolumab biosimilar reached the Indian market in January 2026 at manufacturer-announced prices the company described as roughly a quarter of the reference brand, and the originator's Indian patent protection lapsed in May 2026.
So a lower price is not the warning sign. The supply route is. A CDSCO-approved biosimilar procured through a hospital pharmacy is a real saving, with a traceable batch and an invoice behind it. A discounted vial offered by an agent, a broker, an online seller or a relative's courier is a different proposition entirely — and it is precisely the route counterfeiters and diverters use, because the families most under financial pressure are the ones most likely to take it. Our page on buying immunotherapy medicines outside the hospital sets out the risks and the rules in more detail.
If the pressure is financial rather than clinical, the useful next step is finding out whether a biosimilar exists for the molecule that has been prescribed. Which immunotherapy medicines have Indian biosimilars today lists what is actually marketed here, and the originator versus biosimilar price comparison by molecule sets published figures side by side. Both are sourced from manufacturer announcements and reported prices, dated, and neither is a CION rate card.
One practical caution for anyone budgeting. Published prices are indicative only, as of August 2026, and a vial price is not a course price. Hospital procurement rates, scheme ceilings under Aarogyasri, CGHS, ECHS or ESI, and insurer settlements all differ from a list price. A written per-cycle estimate from the treating hospital's billing desk is worth more than any figure on a web page.
Reading further on authenticity, biosimilars and price
- Buying Immunotherapy Medicines Outside the Hospital: Risks and Rules — why the cheapest route is usually the least verifiable, and what the law actually allows.
- Which Immunotherapy Medicines Have Indian Biosimilars Today? — the legitimate way a price falls, molecule by molecule.
- Originator vs Biosimilar: A Price Comparison by Molecule — published figures side by side, sourced and dated.
- Immunotherapy Medicines Explained — the full reference section this page sits in, including how pricing and regulatory information here is sourced.
- Immunotherapy at CION — the pillar guide to what immunotherapy is, who it suits, and how it is delivered as day care.
This page is editorial reference content, not an offer, a price list, or a recommendation to use any named product. It makes no comparative quality claim between manufacturers. Regulatory positions are cited to Ministry of Health and CDSCO notifications and are current as of August 2026; enforcement details are cited to published police and press reporting; price references are drawn from manufacturer announcements and reported figures, dated, and are indicative only. They are not CION rates, and CION does not state that it stocks or supplies any named product. Whether an immunotherapy medicine has a role in a particular patient's treatment is a decision for the treating oncologist.